Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Two-Step Remission Induction With Risk-Oriented Consolidation (High-Risk: Allogeneic Stem Cell Transplant; Standard-Risk: Multicycle High-Dose Cytarabine With Autologous Blood Stem Cell Support) for Adult Acute Myelogenous Leukemia

NCT00400673 is registered in ClinicalTrials.gov with Northern Italy Leukemia Group as lead sponsor.

NCT NCT00400673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00400673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Two-Step Remission Induction With Risk-Oriented Consolidation (High-Risk: Allogeneic Stem Cell Transplant; Standard-Risk: Multicycle High-Dose Cytarabine With Autologous Blood Stem Cell Support) for Adult Acute Myelogenous Leukemia
Lead sponsor
Northern Italy Leukemia Group
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2000
Completion date
October 31, 2007
Enrollment
581 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia